RxSight, Inc.

Listed Company

RXSTCIK 0001111485NasdaqAcceleratedOphthalmic GoodsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$134.48M

Net Income

$-38.94M

Total Assets

$311.81M

Equity

$275.68M

Shares Out

41.40M

Op. Cash Flow

$-15.51M

RXST$5.56−24.46% · past yearDBEQ Basic

Daily closing prices

Business

RxSight, Inc. is a commercial-stage medical technology company that manufactures and sells the RxSight Light Adjustable Lens system, a proprietary adjustable intraocular lens and light delivery device for customized vision correction following cataract surgery. The company's product comprises the LAL (Light Adjustable Lens), the LDD (Light Delivery Device), and related accessories that enable post-operative refractive adjustments using UV light. RxSight operates primarily in the U.S. premium cataract market through a direct sales model targeting high-volume cataract surgeons, with an installed base of 1,134 LDDs and approximately 300,000 LALs implanted since inception.

Summary from 10-K filed 2026-02-25

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Sales	134	140	89	49	23
Cost of sales	31	41	35	28	18
Gross profit	103	99	54	21	5
Selling, general and administrative	113	101	75	59	33
Research and development	39	34	29	26	24
Total operating expenses	151	136	104	85	57
Loss from operations	−48	−37	−50	−63	−53
Interest expense	−19,000	−21,000	−3	−5	−4
Interest and other income	9	9	7	2	54,000
Loss on extinguishment of term loan	0	0	−2	0	—
Loss before income taxes	−39	−27	−49	−67	−49
Income tax expense	66,000	50,000	20,000	9,000	8,000
Net loss	−39	−27	−49	−67	−49
Unrealized (loss) gain on short-term investments	−136,000	180,000	83,000	−66,000	−7,000
Foreign currency translation gain (loss)	23,000	−9,000	7,000	−9,000	−10,000
Total other comprehensive (loss) income	−113,000	171,000	90,000	−75,000	−17,000
Comprehensive loss	−39	−27	−49	−67	−49
Attributable to common stock, basic (per share)	−0.95	−0.71	−1.41	−2.41	−3.57
Attributable to common stock, diluted (per share)	−0.95	−0.71	−1.41	−2.41	−3.57
Attributable to common stock, basic (shares)	41	39	34	28	14
Attributable to common stock, diluted (shares)	41	39	34	28	14

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	20	17	10	12	24
Short-term investments	208	221	117	94	135
Accounts receivable	23	30	20	11	5
Inventories, net	32	22	17	15	8
Prepaid and other current assets	4	5	4	3	4
Total current assets	287	294	168	135	176
Property and equipment, net	13	12	11	10	11
Operating leases right-of-use assets	10	11	2	4	4
Restricted cash	750,000	750,000	711,000	761,000	811,000
Other assets	590,000	360,000	147,000	767,000	114,000
Total assets	312	319	183	150	193
Accounts payable	5	5	4	3	2
Accrued expenses and other current liabilities	20	20	15	13	8
Lease liabilities	1	974,000	2	2	2
Total current liabilities	26	26	21	17	11
Long-term lease liabilities	10	11	1	3	4
Other long-term liabilities	0	127,000	74,000	0	—
Total liabilities	36	37	22	60	54
Commitments and contingencies (Note 12)	—	—	—	—	—
Common stock, $0.001 par value, 900,000,000 shares authorized, 41,242,005 shares issued and outstanding as of December 31, 2025 and 40,428,220 Shares issued and outstanding as of December 31, 2024	41,000	40,000	36,000	28,000	27,000
Preferred stock, $0.001 par value, 100,000,000 shares authorized, no shares issued and outstanding	0	0	0	0	0
Additional paid-in capital	937	903	755	636	618
Accumulated other comprehensive loss	53,000	166,000	−5,000	−95,000	−20,000
Accumulated deficit	−661	−622	−595	−546	−479
Total stockholders' equity	276	281	160	90	138
Total liabilities and stockholders' equity	312	319	183	150	193

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−39	−27	−49	−67	−49
Depreciation and amortization	3	4	4	4	4
Provision for bad debts	32,000	34,000	0	0	—
Amortization of debt issuance costs and premium	0	0	287,000	552,000	493,000
Amortization of discount on short-term investments	−9	−9	−6	−1	−30,000
Stock-based compensation	32	25	16	11	8
Provision for excess and obsolete inventory	2	404,000	164,000	752,000	2
Accounts receivable	7	−10	−9	−6	−2
Inventories	−11	−5	−3	−8	−2
Prepaid and other assets	1	−1	−397,000	789,000	−3
Accounts payable	627,000	946,000	1	635,000	555,000
Accrued expenses and other liabilities	−2	6	2	5	4
Net cash used in operating activities	−16	−17	−42	−59	−45
Purchases of property and equipment	−4	−5	−5	−2	−2
Maturity of short-term investments	260	243	255	255	80
Purchase of short-term investments	−239	−337	−272	−213	−160
Net cash (used in) provided by investing activities	17	−99	−22	40	−82
Proceeds from term loan	0	0	20	0	15
Repayment of term loan	0	0	−60	0	—
Proceeds from issuance of common stock from public offering	0	108	54	0	120
Proceeds from issuance of common stock for at-the-market offerings	—	0	42	6	—
Proceeds from Issuance of Common Stock	4	21	9	2	—
Payments for employee taxes related to stock compensation	−2	−5	−1	−643,000	0
Principal payments on finance lease liabilities	−26,000	−61,000	−153,000	−121,000	−27,000
Payments of deferred offering costs	0	−768,000	−622,000	−587,000	0
Payments of debt issuance costs	0	0	−2	−145,000	−132,000
Net cash provided by financing activities	2	123	62	6	137
Effect of foreign exchange rate on cash, cash equivalents and restricted cash	3,000	−9,000	6,000	−9,000	−10,000
Net increase (decrease) in cash, cash equivalents and restricted cash	3	7	−2	−13	11
Operating cash flows from operating leases	3	2	2	2	1
Cash paid for income taxes	58,000	24,000	8,000	3,000	20,000
Cash paid for interest on term loan	0	0	3	4	3
Operating lease	29,000	10	46,000	1	126,000
Operating lease	29,000	10	46,000	1	126,000
Acquisition of property and equipment included in accounts payable and accrued expenses and other current liabilities	421,000	545,000	282,000	299,000	0
Deferred offering costs included in accounts payable and accrued liabilities	0	0	145,000	133,000	0
Reclassification of deferred financing costs	0	768,000	1	90,000	3

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is RxSight, Inc.'s CIK number?

RxSight, Inc.'s SEC CIK number is 0001111485 (1111485). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find RxSight, Inc.'s SEC filings?

All of RxSight, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did RxSight, Inc. last report earnings?

RxSight, Inc. (RXST) most recently filed an earnings 8-K with the SEC on Jul 6, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-296200). This is RxSight, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is RxSight, Inc.'s most recent earnings 8-K?

RxSight, Inc.'s latest earnings 8-K (Item 2.02) was filed Jul 6, 2026 under accession 0001193125-26-296200. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View RxSight, Inc.'s latest earnings 8-K →
Look up any company's CIK number →